WO2006017369A3 - Use of a farnesyl transferase inhibitor in the treatment of viral infections - Google Patents
Use of a farnesyl transferase inhibitor in the treatment of viral infections Download PDFInfo
- Publication number
- WO2006017369A3 WO2006017369A3 PCT/US2005/025176 US2005025176W WO2006017369A3 WO 2006017369 A3 WO2006017369 A3 WO 2006017369A3 US 2005025176 W US2005025176 W US 2005025176W WO 2006017369 A3 WO2006017369 A3 WO 2006017369A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- farnesyl transferase
- viral infections
- transferase inhibitor
- farnesyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58777104P | 2004-07-13 | 2004-07-13 | |
US60/587,771 | 2004-07-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006017369A2 WO2006017369A2 (en) | 2006-02-16 |
WO2006017369A3 true WO2006017369A3 (en) | 2006-11-23 |
Family
ID=35839815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/025176 WO2006017369A2 (en) | 2004-07-13 | 2005-07-13 | Use of a farnesyl transferase inhibitor in the treatment of viral infections |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006017369A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999027929A1 (en) * | 1997-12-04 | 1999-06-10 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5919780A (en) * | 1995-06-16 | 1999-07-06 | Warner Lambert Company | Tricyclic inhibitors of protein farnesyltransferase |
WO2002024686A2 (en) * | 2000-09-25 | 2002-03-28 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
-
2005
- 2005-07-13 WO PCT/US2005/025176 patent/WO2006017369A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5919780A (en) * | 1995-06-16 | 1999-07-06 | Warner Lambert Company | Tricyclic inhibitors of protein farnesyltransferase |
WO1999027929A1 (en) * | 1997-12-04 | 1999-06-10 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO2002024686A2 (en) * | 2000-09-25 | 2002-03-28 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
Also Published As
Publication number | Publication date |
---|---|
WO2006017369A2 (en) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007003686A1 (en) | COMPOUNDS DERIVED FROM INDOL WITH UNITED RING IN POSITIONS 4,5; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND TO TREAT A VIRAL INFECTION. | |
WO2008127364A3 (en) | Antiviral compounds and use thereof | |
WO2008003149A3 (en) | Substituted pteridines for the treatment and prevention of viral infections | |
WO2005077050A3 (en) | Hiv integrase inhibitors | |
WO2007041487A3 (en) | Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family | |
WO2008045238A3 (en) | Stabilized therapeutic small helical antiviral peptides | |
MX2010003916A (en) | Spiropyrrolidines and their use against hcv and hiv infection. | |
ECSP077252A (en) | Methods to treat hepatitis C | |
CL2009000305A1 (en) | Compounds derived from 2-aryl-substituted-1-benzofuran-3-carboxamide, ns5b polymerase inhibitors; pharmaceutical composition; and its use in the treatment of a disease caused by the hepatitis c virus (hcv). | |
AP2005003366A0 (en) | Pyrimidine derivatives for the prevention of HIV infection. | |
CL2013000727A1 (en) | Compounds derived from imidazo [1,2-f] [1,2,4] triazinyl nucleosides; pharmaceutical composition that includes them; and its use for the treatment of a flaviviridae virus infection, particularly hepatitis c virus infections. | |
WO2004112687A3 (en) | Antiviral acylguanidine compounds and methods | |
NO20091258L (en) | Entantiomerically pure phosphoindoles as HIV inhibitors | |
EA201200631A1 (en) | Inhibitors of Human Immunodeficiency Virus Replication | |
WO2009055335A3 (en) | Hcv protease inhibitors | |
DK1265889T3 (en) | Drugs for viral diseases | |
ATE534652T1 (en) | PHOSPHONO-PENT-2-EN-1-YL NUCLEOSIDES AND ANALOGS | |
AR052165A1 (en) | HEPATITIS C TREATMENT IN THE ASIAN POPULATION | |
CA2862755A1 (en) | Antiviral compounds with a dibenzooxaheterocycle moiety | |
WO2006054182A3 (en) | Phosphoindoles as hiv inhibitors | |
WO2007019098A3 (en) | Hiv integrase inhibitors | |
WO2010052559A8 (en) | Cycloundecadepsipeptide compounds and use of said compounds as a medicament | |
WO2009021971A3 (en) | Novel targets and compounds for therapeutic intervention of hiv infection | |
WO2009014417A3 (en) | An antiviral composition | |
WO2006019841A3 (en) | Treatment of viral infections with egr 1 activators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |